Pure Global
NCT05659264

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants With Chronic Heart Failure
ModernaTX, Inc.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Heart Failure
Drug/Device/Intervention
mRNA-0184
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
ModernaTX, Inc.
Location
Wroclaw,Lódz,Bialystok,Katowice,Dundee,Plymouth, Poland,United Kingdom
Timeline & enrollment
Phase
Phase 1
Start date
Nov 18, 2022
End date
May 07, 2024
Enrollment
98 participants
Primary outcome

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Summary

The primary objective of this study is to evaluate the safety and tolerability of single and
 multiple doses at escalating dose levels of mRNA-0184.

ICD-10 classifications
Heart failureHeart failure, unspecifiedCongestive heart failureHypertensive heart disease with (congestive) heart failureHypertensive heart disease without (congestive) heart failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05659264
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05659264 through Pure Global AI's free database. This Phase 1 trial is sponsored by ModernaTX, Inc. and is currently Recruiting. The study focuses on Chronic Heart Failure. Target enrollment is 98 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.